<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636775</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-2020-MIP-NSCLC</org_study_id>
    <nct_id>NCT04636775</nct_id>
  </id_info>
  <brief_title>Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)</brief_title>
  <official_title>Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun Zhang, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IV study is hoping to determine if examining the microbiome in non-small cell lung&#xD;
      cancer, immunotherapy naive participants can predict the effectiveness of immunotherapy&#xD;
      treatment as well as determine ahead of time adverse events and their severity. In addition,&#xD;
      the investigator will look into microbiome changing modifiers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiome difference between patients with and without AEs&gt;=grade 3</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Adverse events (AEs) will be graded per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiome difference between responders vs. nonresponders</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Treatment response will be evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of microbiome to tumor tissue PD-L1 expression</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>PD-L1 expression is per standard of care using IHC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of microbiome to diet</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Customized Diet Survey</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">46</enrollment>
  <condition>NSCLC Stage IV</condition>
  <condition>NSCLC, Recurrent</condition>
  <arm_group>
    <arm_group_label>Immunotherapy naïve NSCLC patients</arm_group_label>
    <description>Microbiome in immunotherapy naïve NSCLC patients receiving PD-1/L1 blockade</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Microbiome</intervention_name>
    <description>Nasal and buccal swabs, and stool sample, as well as the extracted DNAs</description>
    <arm_group_label>Immunotherapy naïve NSCLC patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasal and buccal swabs, and stool sample, as well as the extracted DNAs for current and&#xD;
      future, study-related research&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Immunotherapy naïve metastatic/advanced/recurrent NSCLC patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have tumor tissue biopsy-proven to be NSCLC&#xD;
&#xD;
          -  Must have a target lesion to evaluate treatment response&#xD;
&#xD;
          -  Immunotherapy naïve metastatic/advanced/recurrent NSCLC patients&#xD;
&#xD;
          -  Will receive single agent anti-PD-1/PD-L1 therapy (e.g. pembrolizumab, nivolumab,&#xD;
             atezolizumab, avelumab or durvalumab, etc.). Patients can be on other interventional&#xD;
             trial if they will be receiving single agent anti-PD-1/PD-L1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with any forms of cancer immunotherapy&#xD;
&#xD;
          -  Not competent to make medical decision, noncommunicative or noncompliant per treating&#xD;
             physician's judgement&#xD;
&#xD;
          -  Not English-speaking&#xD;
&#xD;
          -  Patients that are pregnant&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Students and employees&#xD;
&#xD;
          -  Psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Kansas Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KUCC Navigation</last_name>
    <phone>9135883671</phone>
    <email>kucc_Navigation@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center (KUCC)</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KUCC Navigator</last_name>
      <phone>913-588-3671</phone>
      <email>kucc_navigation@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center, Westwood Campus</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KUCC Navigation</last_name>
      <phone>913-588-3671</phone>
      <email>kucc_navigation@kumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Swami U, Zakharia Y, Zhang J. Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together. J Immunother. 2018 Oct;41(8):359-360. doi: 10.1097/CJI.0000000000000232. Review.</citation>
    <PMID>29781826</PMID>
  </reference>
  <reference>
    <citation>Strouse C, Mangalam A, Zhang J. Bugs in the system: bringing the human microbiome to bear in cancer immunotherapy. Gut Microbes. 2019;10(2):109-112. doi: 10.1080/19490976.2018.1511665. Epub 2018 Sep 5.</citation>
    <PMID>30183502</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Jun Zhang, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor; Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Advanced NSCLC</keyword>
  <keyword>Metastatic NSCLC</keyword>
  <keyword>Recurrent NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

